0000950170-23-034518.txt : 20230725
0000950170-23-034518.hdr.sgml : 20230725
20230725183646
ACCESSION NUMBER: 0000950170-23-034518
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230721
FILED AS OF DATE: 20230725
DATE AS OF CHANGE: 20230725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciaramella Giuseppe
CENTRAL INDEX KEY: 0001786322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39208
FILM NUMBER: 231109720
MAIL ADDRESS:
STREET 1: C/O BEAM THERAPEUTICS INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beam Therapeutics Inc.
CENTRAL INDEX KEY: 0001745999
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-327-8775
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0508
4
2023-07-21
0001745999
Beam Therapeutics Inc.
BEAM
0001786322
Ciaramella Giuseppe
C/O BEAM THERAPEUTICS INC.
238 MAIN STREET
CAMBRIDGE
MA
02142
false
true
false
false
President and CSO
true
Common Stock
2023-07-21
4
M
false
69438
7.22
A
181728
D
Common Stock
2023-07-21
4
M
false
21846
7.22
A
203574
D
Common Stock
2023-07-21
4
S
false
155324
32.06
D
48250
D
Common Stock
2023-07-24
4
M
false
1206
7.22
A
49456
D
Common Stock
2023-07-24
4
S
false
1206
32.01
D
48250
D
Stock Option (Right to Buy)
7.22
2023-07-21
4
M
false
69438
0
D
2029-05-17
Common Stock
69438
20208
D
Stock Option (Right to Buy)
7.22
2023-07-21
4
M
false
21846
0
D
2029-05-31
Common Stock
21846
1457
D
Stock Option (Right to Buy)
7.22
2023-07-24
4
M
false
1206
0
D
2029-05-17
Common Stock
1206
19002
D
The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
These shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.11, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.00 to $32.095, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This stock option vests as to 25% on the first anniversary of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.
By: /s/ Christine Bellon, Attorney-in-fact
2023-07-25